Genetic Variation in <i>CYP2D6</i>, <i>UGT1A4</i>, <i>SLC6A2</i> and <i>SLCO1B1</i> Alters the Pharmacokinetics and Safety of Mirabegron

• Hoofdauteurs: Paula Soria-Chacartegui (Auteur), Patricia Cendoya-Ramiro (Auteur), Eva González-Iglesias (Auteur), Samuel Martín-Vílchez (Auteur), Andrea Rodríguez-Lopez (Auteur), Gina Mejía-Abril (Auteur), Manuel Román (Auteur), Sergio Luquero-Bueno (Auteur), Dolores Ochoa (Auteur), Francisco Abad-Santos (Auteur)
• Formaat: Boek
• Gepubliceerd in: MDPI AG, 2024-08-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Mirabegron is a drug used in overactive bladder (OAB) treatment. Genetic variation in pharmacogenes might alter its pharmacokinetics, affecting its efficacy and safety. This research aimed to analyze the impact of genetic variation on mirabegron pharmacokinetics and safety. Volunteers from three bio...